AbbVie (ABBV) and Roche’s (RHHBY) Genentech have revealed positive results from the Phase III VIALE-A study, evaluating Venclexta (venetoclax) with azacitidine in people with previously untreated acute myeloid leukemia (AML) who were ineligible for intensive induction chemotherapy.The results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on June 13.“The significant survival benefits observed in the VIALE-A study reinforce the potential utility of this Venclexta-based combination for people with this aggressive disease” commented Levi Garraway, CMO at Genentech.Indeed, AML is the most common type of aggressive leukemia in adults, which has the lowest survival rate for all …read more
Source:: Yahoo Finance
